The Food and Drug Administration approved the drug for adult patients with bullous pemphigoid, which mainly affects the ...

The US FDA has approved Sanofi and Regeneron’s Dupixent (dupilumab) as a treatment option for adults with bullous pemphigoid.

SNY and REGN's Dupixent gets FDA approval for a rare and chronic skin disease, marking its eighth approved indication for the ...

Dupixent approved by FDA for bullous pemphigoid, offering a new option for adults with the rare autoimmune skin disease ...

Regeneron shows financial strength and fair valuation, but trevogrumab's Phase 2 progress adds uncertainty. Click here to ...

Sanofi and Regeneron’s Dupixent (dupilumab) has been approved by the US Food and Drug Administration (FDA) to treat bullous ...

SNY trades below key moving averages but strong Dupixent growth, pipeline wins and rising estimates may keep bulls invested.

Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi (SNY) on Friday announced that the U.S. Food and Drug Administration (FDA) ...

Sanofi and Regeneron Pharmaceuticals said they got Food and Drug Administration approval for anti-inflammatory drug Dupixent as a treatment for a rare skin disease, adding an eighth indication in ...

FDA approves first targeted therapy for bullous pemphigoid (BP): Dupixent (dupilumab) becomes the first and only targeted treatment approved for adults with this rare autoimmune blistering disease.

IL-4 and IL-13 inhibitor Dupixent (dupilumab) is the first biologic drug to show an improvement in remission and symptoms in ...